Abstract
The Phosphatidylinositol 3-kinase/AKT/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) pathway has a critical regulatory role in cell biology including translation, transcription, and autophagy. Dysregulation of this pathway is involved in the pathogenesis, development, and prognosis of esophageal cancer that has been assessed in the recent years and its potential as a target in therapy. This report summarizes the current knowledge about PI3K/AKT/mTOR pathway and its cross-talk with a focus on the value of targeting this pathway as a potential therapeutic target in the treatment of esophageal cancer.
Keywords: PI3K/AKT/mTOR pathway, microRNAs, esophageal cancer, rapamycin, translation, transcription.
Current Pharmaceutical Design
Title:The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy
Volume: 24 Issue: 39
Author(s): Seyed A. Javadinia, Soodabeh Shahidsales, Azar Fanipakdel, Asma Mostafapour, Mona Joudi-Mashhad, Gordon A. Ferns and Amir Avan*
Affiliation:
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: PI3K/AKT/mTOR pathway, microRNAs, esophageal cancer, rapamycin, translation, transcription.
Abstract: The Phosphatidylinositol 3-kinase/AKT/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) pathway has a critical regulatory role in cell biology including translation, transcription, and autophagy. Dysregulation of this pathway is involved in the pathogenesis, development, and prognosis of esophageal cancer that has been assessed in the recent years and its potential as a target in therapy. This report summarizes the current knowledge about PI3K/AKT/mTOR pathway and its cross-talk with a focus on the value of targeting this pathway as a potential therapeutic target in the treatment of esophageal cancer.
Export Options
About this article
Cite this article as:
Javadinia A. Seyed, Shahidsales Soodabeh , Fanipakdel Azar , Mostafapour Asma , Joudi-Mashhad Mona , Ferns A. Gordon and Avan Amir *, The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/1381612825666190110143258
DOI https://dx.doi.org/10.2174/1381612825666190110143258 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Protein & Peptide Letters Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology Peptide-Based Nanostructures for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Takotsubo Cardiomyopathy
Current Pharmaceutical Design Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Current Pharmaceutical Design Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets The Regulatory Role of Both MBNL1 and MBNL1-AS1 in Several Common Cancers
Current Pharmaceutical Design Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Current Signal Transduction Therapy The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Ent-11α-Hydroxy-15-Oxo-Kaur-16-en-19-Oic-Acid Induces Apoptosis of Human Malignant Cancer Cells
Current Drug Targets p16<sup>INK4</sup> as a Biomarker in Oropharyngeal Squamous Cell Carcinoma
Recent Patents on Biomarkers Nanocrystal Technology in the Delivery of Poorly Soluble Drugs: An Overview
Current Drug Delivery MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1
Current Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics